ClinicalTrials.gg
CompletedNCT07289464Updated Aug 17, 2026

A Clinical Study of RSS0343 in Healthy Subjects

A Phase 1 interventional study of RSS0343 Tablets and RSS0343 Tablets Placebo in Non-cystic Fibrosis Bronchiectasis, sponsored by Reistone Biopharma Company Limited. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Reistone Biopharma Company Limited (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies in Bronchiectasis with a site in China — 35 open to participants now, 38 under way, 4 of them phase 3. Bronchiectasis · China.

Enrollment
40th of 50
48 · median 120
Started
2026
with 8 others
Phase 1
6 of 84
5 open now
Registered
72nd of 84
by date

Among the 84 studies in Bronchiectasis with a site in China, this one is the 40th largest by enrollment of the 50 interventional ones that give a count, is one of 9 that started in 2026, is one of 6 in phase 1, and was the 72nd registered.

Bronchiectasis

404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

35 of the 84 studies in Bronchiectasis with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Bronchiectasis with a site in China, or all of them as a file.
02

Study summary

This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of RSS0343 following multiple oral doses in healthy subjects, as well as its effects on the QT/QTc interval.

03

Conditions studied

  • Non-cystic Fibrosis Bronchiectasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who provided written after being fully informed of the trial's purpose, significance, and protocol requirements.
  2. Healthy individuals aged 18 to 55 years, inclusive. Males and females
  3. Body weight ≥ 50 kg for males and ≥ 45 kg for females. (BMI) = weight (kg)/height 2 (m²). BMI between 19 and 28 kg/m², inclusive.
  4. Fertile male and female subjects and their partners must agree to use highly effective as stipulated in the protocol, from screening until 6 months (for females) or 3 months (for males) after the last dose. Additionally, fertile female subjects must have a negative serum pregnancy test at screening and prior to the first dose (baseline) and must not be lactating.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who smoked more than 5 cigarettes (or equivalent nicotine products) daily within 3 months prior to screening or intended to use tobacco products during the trial.
  2. Subjects with frequent alcohol consumption (>15 g/day for females or >25 g/day for males [5g of alcohol is equivalent to 150 mL of beer, 50 mL of wine or approximately 17 mL of low-alcohol liquor], on more than 2 occasions per week) within 6 months prior to screening, or were unable to abstain during the trial, or who tested positive on the alcohol breath test at baseline.
  3. Subjects with a history of, or current, drug abuse, or drug dependence (during consultation), or with a positive urine drug screening result.
  4. Subjects who had donated blood or experienced a total blood loss of ≥200 mL within 1 month, or ≥400 mL within 3 months prior to dosing, or who had received a blood transfusion within 8 weeks prior to dosing.
  5. Subjects with dysphagia; or a history of needle or blood phobia, poor venous access, or inability to tolerate venipuncture.
  6. Subjects deemed by the investigators to be unsuitable for the trial for any other reason.
  7. Subjects with any abnormalities, as determined by the investigator, in physical examination, vital signs, laboratory tests (including hematology, urinalysis, blood biochemistry, coagulation), chest imaging, abdominal ultrasonography, or .
  8. Subjects who tested positive for surface antigen, antibody, syphilis antibody or antibody.
  9. Subjects with a known or suspected allergy to the drug or its , or a history of severe allergic reactions (e.g., to drugs, food, toxins).
  10. Subjects with any active disease or immunodeficiency at screening.
  11. Subjects with any history of severe clinical disease, or any condition that, in the investigator's judgment, could compromise trial outcomes, affect drug absorption, distribution, metabolism, or excretion (pharmacokinetics), or pose an undue risk to the subject. This includes, but is not limited to, significant disorders of the circulatory, endocrine, nervous, digestive, urinary, hematological, immune, psychiatric, or metabolic systems.
  12. Subjects who had undergone any surgery within 3 months prior to screening, had not fully recovered as determined by the investigator, or planned to undergo surgery during the trial or within 1 month after its completion.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    RSS0343 Tablets Group

    Drug: RSS0343 Tablets

  • Placebo comparator
    RSS0343 Tablets Placebo Group

    Drug: RSS0343 Tablets Placebo

Interventions

  • RSS0343 tablets, oral.

  • DrugRSS0343 Tablets Placebo

    RSS0343 tablets placebo, oral.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of any adverse events (AEs).

    Safety and tolerability.

    Time frame: Evaluation was performed up to Day 28.

Secondary outcomes

  1. Maximum observed plasma concentration of RSS0343 at Day 1 (Cmax).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  2. Maximum observed plasma concentration of RSS0343 at steady state (Cmax,ss).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  3. Time to Cmax (Tmax).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  4. Time to Cmax,ss (Tmax,ss).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  5. Area under the concentration-time curve during a dosing interval (AUC0-tau).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  6. Area under the concentration-time curve from 0 to the last measurable time point after RSS0343 administration (AUC0-t).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  7. Area under the concentration-time curve from time 0 to infinity after RSS0343 administration (AUC0-inf).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  8. Terminal elimination half-life of RSS0343 (t1/2).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  9. Apparent clearance of RSS0343 during multiple dosing with a dosing interval of time tau (CLss/F).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  10. Apparent volume of distribution during terminal elimination phase of RSS0343 at steady state (Vss/F).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  11. Cumulative amount of drug excreted in urine (Ae,urine).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  12. Cumulative percentage of dose recovered in urine (Fe,urine).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  13. Renal clearance of RSS0343 (CLr).

    Pharmacokinetics (PK) indicator.

    Time frame: Evaluation was performed up to Day 28.

  14. Changes in the QTc interval corrected by the Fridericia method relative to baseline (ΔQTcF) (where applicable).

    To evaluate the effects of RSS0343 on the QT/QTc interval in healthy subjects.

    Time frame: Evaluation was performed up to Day 28.

07

Study locations

1 site
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430071, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Aug 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Dec 17, 2025
StartActual
Jan 8, 2026
Primary completionActual
Aug 10, 2026
CompletionActual
Aug 10, 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07289464
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Jan 8, 2026
Primary completion
Aug 10, 2026
Completion
Aug 10, 2026
Last update
Aug 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RSS0343

Start the discussion